id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-275584-zeqax0il	Mahil, S. K.	Risk mitigating behaviours in people with inflammatory joint and skin disease during the COVID-19 pandemic differ by treatment type: a cross-sectional patient survey	2020-11-07		.txt	text/plain	4056	241	47	Objectives Registry data suggest that people with immune-mediated inflammatory diseases (IMIDs) receiving targeted systemic therapies have fewer adverse COVID-19 outcomes compared to patients receiving no systemic treatments. Global clinician-reported registry data in rheumatic diseases, psoriasis and inflammatory bowel disease have further suggested a differential risk of severe COVID-19 associated with different treatment types. We focused on RMDs and psoriasis as representative IMIDs and used global self-report survey data to explore the notion that individuals receiving different types of treatment exhibit distinct risk mitigating behaviours in the pandemic. Self-reported data from 3,720 individuals with a primary diagnosis of RMD (851, 22.9%) or psoriasis (2869, 77.1%) were available from 74 countries (including UK (2,578, 69.4%), Portugal (200, 5.4%), USA (165, 4.5%)) (demographic/clinical/socio-economic descriptions, CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.	./cache/cord-275584-zeqax0il.txt	./txt/cord-275584-zeqax0il.txt